We tested using TC-1, a mouse tumor model where vaccine is used to prime the immune system and assessed the effects of agonist anti-OX40 antibody (1 mg/kg twice weekly) combined with a ROR-gamma agonist (LYC-54143; 100 mg/kg BID given continuously till the end of study) on growth of established tumors and survival. The gene discussed is TNFRSF4; the disease is neoplasm.